NCT06878729Recruiting
Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI
Antegrade Dissection and Re-entry Versus Retrograde Strategy in Chronic Total Occlusion Percutaneous Coronary Intervention
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
The ADRENALINE trial has been designed as a multi-center, prospective randomized study to compare the procedural and periprocedural outcomes of coronary chronic total occlusion (CTO) percutaneous coronary intervention (PCI) using antegrade dissection and re-entry (ADR) versus retrograde strategy. Beyond the patient-oriented outcomes, the influence of the studied CTO PCI strategies on the stress levels among interventional cardiologists will be explored. The main questions it aims to answer are as follows: * What is the difference between ADR versus retrograde strategy with regard to total procedure time, the rates of successful guidewire crossing and periprocedural complications as well as stress levels experienced by interventional cardiologists? * Is retrograde approach associated with higher rates of myocardial injury/infarction based on cardiac troponin/cardiac magnetic resonance (CMR) as compared with ADR? Participants will undergo pre- and postprocedural laboratory testing (cardiac troponin, CK-MB), CMR for late gadolinium enhancement and health status assessment. Subjects undergoing successful CTO PCI using antegrade wiring strategy will be included in the observational arm.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 74 (estimated)
- First submitted
- 4 Mar 2025
- Start date
- 28 Jul 2025
- Primary completion date
- 31 Mar 2028
- Lead sponsor
- National Institute of Cardiology, Warsaw, Poland
- Diseases
- Coronary artery disease
- NCT number
- NCT06878729
What you commit to
- Study type: Interventional
- Planned participants: 74
- From 28 Jul 2025 to the primary completion date, 31 Mar 2028
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- acute myocardial infarction
- severe valvular disease
- contrast allergy
Age
- \<18 years of age
Other
- cardiogenic shock
- estimated life expectancy \<1 year
- contraindication to PCI
- positive pregnancy test or breast-feeding
- native CTO lesion with easy or intermediate difficulty score on invasive angiography (J-CTO score \<2 points)
- lack of angiographic equipoise between the ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators
Who the study is looking for
- clinical indication for CTO PCI as determined by the local heart team (presence of angina or equivalent symptoms and/or documented ischemia or viability)
- at least difficult native CTO lesion with J-CTO difficulty score ≥2 points on invasive angiography
- angiographic suitability for both ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators
- informed consent for participation in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital of the Ministry of the Interior and Administration Coordinator of this site? Confirm its status | Lublin | Poland | Recruiting |
| 1st Military Clinical Hospital Coordinator of this site? Confirm its status | Lublin | Poland | Recruiting |
| National Institute of Cardiology Coordinator of this site? Confirm its status | Warsaw | Poland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.